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Abstract
Objective: Cytokines play important roles in mediating inflammation in autoimmunity. Several
cytokines are elevated in serum and synovial fluid samples from children with Juvenile Idiopathic
Arthritis (JIA). Soluble CD154 (sCD154) is elevated in other autoimmune disorders, but has not
been characterized in JIA. Our objectives were to determine if sCD154 is elevated in JIA, and to
examine correlations between sCD154 and other inflammatory cytokines.
Methods: Serum from 77 children with JIA and 81 pediatric controls was analyzed for interleukin
(IL)1β, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, sCD154, interferon-γ (IFNγ), soluble IL2 receptor
(sIL2R), and tumor necrosis factor-α (TNFα), using the Luminex Multi-Analyte Profiling system.
Differences in levels of cytokines between cases and controls were analyzed. Logistic regression
was also performed.
Results: sCD154 was significantly elevated in cases compared to controls (p < 0.0001). IL1β, IL5,
IL6, IL8, IL13, IFNγ, sIL2R, and TNFα were also significantly elevated in JIA. Levels of sCD154 were
highly correlated with IL1β, IL6, IL8, and TNFα (p < 0.0001). Logistic regression analysis suggested
that IL6 (odds ratio (OR): 1.4, p < 0.0001), sCD154 (OR: 1.1, p < 0.0001), and TNFα (OR: 1.1, p
< 0.005) were positively associated with JIA, while IL10 (OR: 0.5, p < 0.002) was protective.
sCD154 was elevated in all JIA subtypes, with highest levels among more severe subtypes. IL1β, IL6,
IL8, sIL2R and TNFα were also elevated in several JIA subtypes.
Conclusion: Serum levels of sCD154, IL1β, IL6, IL8, sIL2R and TNFα are elevated in most JIA
subtypes, suggesting a major role for sCD154, and these cytokines and cytokine receptors in the
pathogenesis of JIA.
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Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous
group of arthropathies of unknown etiology. Both genetic
and environmental factors are believed to play a role in
susceptibility to JIA. One way to improve the understand-
ing of the etiopathogenesis of JIA is to define better bio-
logical phenotypes of JIA. A common feature of the
different subtypes of JIA is a tumor-like expansion of the
inflamed synovial tissue, which is infiltrated by inflam-
matory cells including macrophages, plasma cells and
lymphocytes. The production of inflammatory cytokines
by these cells is thought to be instrumental in the devel-
opment and perpetuation of the inflammatory arthritis.
Several cytokines secreted by activated macrophages and
lymphocytes such as interleukin (IL)1, IL6, and tumor
necrosis factor-α (TNFα) have been implicated in the per-
petuation of inflammatory response in JIA [1]. Other
studies have implicated IL1β, IL6, IL8, soluble IL2-recep-
tor (sIL2R), and TNFα in JIA [2-9].
CD40 is a member of the TNF-receptor family which is
expressed on the surface of antigen presenting cells
including B-cells, activated macrophages, dendritic cells
and monocytes [10]. Signaling through CD40 induces
antigen presenting cells to express different immune
accessory molecules important in cell-cell interactions
[11]. CD40 interacts with CD40 ligand (CD40L or
CD154) which is predominantly expressed on activated
CD4+ T-cells [12]. CD154 is transiently expressed on acti-
vated T-cells and plays a crucial role in B-cell function
[13]. Activated T-cells expressing CD154 can also interact
with CD40 on endothelial cells to induce production of
inflammatory cytokines [14]. The transient expression of
CD154 allows T-cells to stimulate selected CD40-bearing
cells to participate in the immune response. Abnormal
expression of CD154 has been reported in patients with
systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) [15,16].
In addition to existing in a membrane bound form,
CD154 can also be released as a soluble molecule
(sCD154), which has been shown to have biological func-
tions [17]. Increased levels of sCD154 have been demon-
strated in patients with SLE, [18], RA, [19], inflammatory
bowel diseases (IBD) [20], systemic sclerosis [21,22] and
Sjogren's syndrome [23]. To our knowledge the concen-
trations and possible role of sCD154 has not been inves-
tigated in JIA. Our objectives were to examine the levels of
multiple cytokines including sCD154 in children with JIA
and healthy controls, and to determine the association of
sCD154 with other inflammatory cytokines reported to be
elevated in JIA. We also sought to determine if sCD154
levels differed between the different subtypes of JIA.
Methods
Serum samples were obtained from 77 children (63%
female) who fulfilled the International League of Associa-
tions for Rheumatology (ILAR) criteria for the diagnosis
of JIA [24]. There were 10 patients each with systemic JIA
and rheumatoid factor (RF)-positive polyarticular JIA, 14
with RF-negative polyarticular JIA, 20 with persistent oli-
goarticular JIA, 11 with extended oligoarticular JIA and
with enthesitis related arthritis (ERA), and 1 with undif-
ferentiated arthritis. The mean age of onset of JIA in the
patients was 7.5 years. A total of 81 pediatric controls
(52% female) were also studied with a mean age of 12
years (range 7–16 years). Controls were children obtained
from an Associated Regional and University Pathologists
(ARUP) institute of clinical and experimental pathology
children's normal values study. The majority of the cases
and controls were of Northern European ancestry. Serum
was separated from peripheral blood soon after being
drawn from subjects and aliquots were stored at -80°C
until the time of cytokine determination. Subjects were
enrolled after providing informed consent, under proto-
cols approved by the Institutional Review Board of the
University of Utah.
Table 1: Disease activity and medication information of children with JIA
Variable All JIA Systemic RF poly Oligo Ext ERA
Number 77 10 10 14 20 11 11
Onset age (years) 7.5 5.4 10 8.0 7.3 4.4 10.6
Median joints (n) 2.5 5 8 7 2 2.5 3.5
ESR (mm Hg) 23 49 26 17 18 28 11
Median number of medications 1 2 1.5 1 1 1 1
Proportion on NSAIDS % 71 50 80 61.5 89 44 90
Proportion on DMARDS % 46 60 70 61.5 16 22 50
Proportion on methotrexate % 25 30 60 46.2 0 0 30
Proportion on an anti-TNF agent% 19 40 10 30 5 22 20
Proportion on Corticosteroids % 12.5 50 10 23 0 0 0
NSAID: non steroidal anti-inflammatory drug, DMARD: disease modifying anti-rheumatic drugPediatric Rheumatology 2008, 6:8 http://www.ped-rheum.com/content/6/1/8
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Information about disease variables at the time of enroll-
ment was available on 72 children with JIA. Active disease
was defined as having arthritis in at least 1 joint. Seven
children did not have active disease. Variables collected
included number of affected joints, ESR, and medications
used to treat JIA at the time of enrollment (table 1). At the
time of collection, 71% were on a non-steroidal anti
inflammatory agent, 46% were on a disease modifying
anti-rheumatic drug, 25% were on methotrexate, 19%
were on an anti-TNF agent, and 12% were on corticoster-
oids.
Multiplexed Cytokine Assay
The Luminex Multi-Analyte Profiling system (Luminex
Corp, TX), is a flow cytometry based instrument that
allows multiple analytes to be assayed simultaneously in
a single sample [25]. The technology is based on the proc-
ess of internally labeling 5.6 μm polystyrene microspheres
with two fluorescent fluorophores. As the microsphere
passes through the flow cell, it is interrogated by two
lasers. One laser identifies the microsphere based on the
ratio of the two fluorophores contained within the micro-
sphere, while the other laser quantitates the amount of
analyte bound to the microsphere by the intensity of
reporter fluorescence. The surface of each microsphere
contains multiple carboxyl groups that function as sites
for covalent ligand attachment. The amount of analyte
bound to the microspheres is determined by the median
fluorescence intensity (MFI) of the reporter molecule,
phycoerythrin, which is conjugated to a secondary or
"detection" antibody.
The multiplexed cytokine assay we used was developed in
the ARUP Institute for Clinical and Experimental Pathol-
ogy, University of Utah using a standard sandwich capture
format and has been described previously [26,27]. Briefly,
monoclonal antibodies to human IL1β, IL2, IL4, IL5, IL6,
IL8, IL10, IL12 p70, IL13, sCD154, IFNγ, sIL2Rα, and
TNFα were used as capture antibodies and coupled to car-
boxylated Luminex microspheres using a two-step carbo-
diimide reaction [28]. A standard curve for each cytokine
was made using known concentrations of recombinant
human cytokine. The subject's sample (75 μl) was diluted
1:2 using a sample diluent and incubated for 10 minutes
on an orbital plate shaker before the addition of the cap-
ture antibody coupled microspheres to allow for absorp-
tion of heterophile antibodies [27]. The cytokine
standards, control samples, patient samples and micro-
spheres were incubated for 1 hour at room temperature
on an orbital plate shaker using 96-well filter bottom
microtiter plate (Millipore Corporation, MA) to allow for
subsequent washing by vacuum filtration. This was fol-
lowed by the addition of 100 μl of a mixture of 13 differ-
ent biotinylated secondary monoclonal antibodies to
complete the sandwich capture assay. Following a second
30 minute incubation on the orbital plate shaker and
washing, 100 μl of 5 μg/mL of streptavidin conjugated R-
phycoerythrin (Moss Substrates, MD) was added to each
well. After a 15-minute incubation and final wash, the
microspheres were resuspended in 100 μl of PBST (10
mM phosphate buffered saline with 0.02% Tween 20),
and the 96-well microplate was placed in a Luminex 100
instrument with an automated microtiter plate handler.
The MFI of the unknown subject's sample was then con-
verted into a pg/mL value based on the known cytokine
concentrations of the standard curve using a 5-parameter
regression formula.
Table 2: Serum cytokine levels in healthy pediatric controls and in patients with JIA.
Controls
N = 81
Cases
N = 77
P value
Cytokine Mean Median IQR Mean Median IQR
IL1β 6.8 0.6 0–3.5 120.9 11 3.4–73 <0.0001
IL2 1.3 0 0–0 12.9 0 0–0 0.31
IL4 0.6 0 0–0.2 5 0 0–0.9 0.07
IL5 0.2 0 0–0 7.7 0.4 0–1.6 <0.0001
IL6 1.7 0.6 0–1.8 196.7 14.2 4.8–114 <0.0001
IL8 2.3 2 0–4.2 149.5 19.3 0.6–91.3 <0.0001
IL10 3.3 2.0 1.6–3.2 8.2 2.9 1.3–8.4 0.07
IL12 5.4 0 0–3.2 3.9 0 0–1.4 0.44
IL13 0.8 0 0–0.4 178.7 19 0–181.1 < 0.0001
sCD154 58.2 19 4.2–73.2 336.1 211.4 148.7–363.9 < 0.0001
IFNγ 0.3 0 0–0 4 0 0–0 0.001
sIL2R 796.8 785.1 611.8–962.9 1125 967.3 553.7–1436.9 0.026
TNFα 2.9 0 0–0 88.5 15 0–70.7 <0.0001
IQR, Interquartile range; IL, Interleukin; sCD154, soluble CD154; IFNγ, interferon-γ; sIL2R, soluble IL2 receptor; TNFα, tumor necrosis factor-α; 
All values median (range) are expressed in pg/ml.Pediatric Rheumatology 2008, 6:8 http://www.ped-rheum.com/content/6/1/8
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Statistical Analysis
Results are expressed as means, median and inter-quartile
ranges. As most of the cytokine levels were not distributed
normally, Wilcoxon two-sample tests were used to com-
pare levels of cytokines between cases and controls. Cor-
relations were determined using the Spearman's rank
order correlation test. We also performed a stepwise logis-
tic regression analysis to evaluate the effect of different
cytokines on disease status. To make the ranges compara-
ble, levels of sCD154 and sIL2R were divided by a factor
of 10 for the regression analysis. Odds ratios (OR) and
95% confidence intervals were calculated. The Hosmer
and Lemeshow statistic was calculated to assess the good-
ness-of-fit of the regression model. Goodness-of-fit statis-
tics examine the difference between the observed
frequency and expected frequency for groups of patients.
A p value < 0.05 would suggest that the model is not well
calibrated. Secondary analyses included comparison of
cytokine levels between different JIA subtypes versus con-
trols. We also compared the disease activity and treatment
characteristics of children in the top tertile for sCD154
with those in the lower tertile. All comparisons were per-
formed using SAS 9.1.
Results
The serum levels of IL1β, IL5, IL6, IL8, IL13, sCD154,
IFNγ, sIL2R, and TNFα were highly significantly elevated
in cases compared to the controls (Table 2). Levels of IL2,
IL4, IL10 and IL12 were not significantly different
between cases and controls. The levels of IL2, IL4, IL5, and
IFNγ were lower than 5 pg/ml in over 90% of subjects,
while the levels of IL12 were lower than 5 pg/ml in 85%
of subjects. The median levels of IL2, IL4, IL5, IL12, and
IFNγ, were ~0 pg/ml among both cases and controls
(Table 2). For this reason, these five cytokines were not
included in subsequent analyses.
Correlation and regression analyses
When we performed correlation analyses, we found that
sCD154 was highly positively correlated with the pro-
inflammatory cytokines IL1β, IL6, IL8 and TNFα (p <
0.0001), and is also positively correlated with sIL2R and
IL13 (p < 0.01) (Table 3). We also tested whether sCD154
levels had a relationship to age to determine if there were
age related changes in our cohorts. There were no correla-
tions between age at the time of collection, and levels of
sCD154 or any of the other cytokines. When we examined
correlations between disease activity variables and
cytokine levels in cases, we found that ESR positively cor-
related with IL6 (p < 0.02), and number of joints (p <
0.02). The levels of TNFα correlated positively with the
number of joints (p < 0.05) and number of medications
(p < 0.003). There were no correlations between sCD154
levels and disease activity variables.
Since these cytokines were correlated with each other, we
performed regression analyses. The Hosmer and Leme-
show goodness of-fit statistic was not-significant (p >
0.11) suggesting the model is well calibrated and fits
agreeably with the data. The logistic regression procedure
identified four cytokines with statistical significance: IL6
with an OR of 1.4 (1.19–1.67, p < 0.0001), IL10 with OR
of 0.46 (0.30–0.69, p < 0.001), TNFα with an OR of 1.08
(1.02–1.13, p < 0.005) and sCD40 with OR of 1.14 (1.07
to 1.21. p < 0.0001).
Comparisons of cytokine levels among JIA subtypes and 
controls
We also compared the cytokine levels between patients
with different JIA subtypes and healthy controls (Table 4).
sCD154, IL1 β, IL6 and TNFα levels were remarkably ele-
vated in all subtypes compared to controls albeit at differ-
ent levels of significance (Table 4 and figure 1). Of note,
Table 3: Spearman Correlation Coefficients of the cytokines.
IL1 β IL6 IL8 IL10 IL13 sCD154 sIL2R TNFα
IL1 β 1.00 0.65 0.54 0.46 0.37 0.55 0.28 0.63
<.0001 <.0001 <.0001 <.0001 <.0001 0.0003 <.0001
IL6 1.00 0.59 0.46 0.30 0.47 0.31 0.63
<.0001 <.0001 0.0001 <.0001 <.0001 <.0001
IL8 1.00 0.29 0.18 0.38 0.17 0.44
0.0002 0.03 <.0001 0.0327 <.0001
IL10 1.00 0.27 0.20 0.46 0.35
0.0006 0.0107 <.0001 <.0001
IL13 1.00 0.22 0.19 0.32
0.0057 0.017 <.0001
sCD154 1.00 0.23 0.45
0.0038 <.0001
sIL2R 1.00 0.29
0.0002
TNFα 1.00
IL, Interleukin; sCD154, soluble CD154; IFNγ, interferon-γ; sIL2R, soluble IL2 receptor; TNFα, tumor necrosis factor-α; Spearmann correlation 
coefficients between various pairs of cytokines and p values are shown.Pediatric Rheumatology 2008, 6:8 http://www.ped-rheum.com/content/6/1/8
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sCD154 levels were most increased in children with RF+
polyarticular and systemic JIA as well as ERA than in the
other types of disease. The highest levels of IL1 β was seen
in patients with RF+ polyarticular JIA while IL6 was most
elevated in patients with systemic and polyarticular JIA.
IL8, IL10 and IL13 were significantly elevated in specific
JIA subtypes compared to controls (Table 4). The highest
levels of IL8 and IL13 were observed in children with pol-
yarticular JIA. IL10 was significantly elevated in polyartic-
ular as well as systemic JIA. Lastly, sIL2R was most
associated with the more severe forms of JIA namely; sys-
temic, RF+ and RF- polyarticular JIA.
Comparison of sCD154 levels with disease activity
When we compared children in the top tertile for sCD154
with those in the lower tertile, those in the upper tertile
had a greater ESR (28 vs. 14) and greater median number
of joints (4.5 vs. 2), but these differences were only mar-
ginally significant (p < 0.09). There were no statistically
significant differences in the proportion of those on
NSAIDs, disease modifying anti-rheumatic agents, meth-
otrexate or anti-TNF agents between children in the top
tertile for sCD154 and those in the lower tertile.
Discussion
Utilizing a multiplex assay for cytokines and inflamma-
tory markers, we characterized the profile of these biomar-
kers in a well defined cohort of JIA patients and controls.
We observed striking elevations of a number of cytokines.
Of special interest to us were the increased serum levels of
sCD154 in children with different JIA subtypes. This ele-
vation was most pronounced in children with systemic,
RF-positive polyarticular and ERA subtypes, and modest
among children with the oligoarticular subtypes. To our
knowledge, ours is the first study to investigate sCD154
levels in JIA. Elevated levels of sCD154 have been found
in other autoimmune disorders including SLE, RA, IBD,
systemic sclerosis and Sjogren's syndrome [18-23].
Expression of CD40 on synovial monocytes, fibroblasts
and dendritic cells in RA has been reported [29,30]. After
stimulation in vitro, peripheral blood T-cells from
patients with RA had increased and longer expression of
CD154 compared to T-cells from controls [16]. Blocking
CD40 on synovial fibroblasts from RA patients with solu-
ble anti-CD40 antibodies prior to co-culture with synovial
mononuclear cells resulted in decreased TNFα levels [16].
Moreover, blockade of CD154 with an antibody amelio-
rates collagen induced arthritis in a murine model of RA
[31]. These observations suggest a major role for CD154
in the perpetuation of inflammation in RA.
The inflammation in synovial tissue of children with JIA
is characterized by the presence of antigen presenting cells
and activated T-cells, and is indistinguishable from the
pathology observed in patients with RA [32]. Our results
suggest that sCD154 might also play a role in the patho-
genesis of most of the JIA subtypes. It is conceivable that
the activated CD4 T-cells in JIA synovium may be the
source of sCD154, although it is possible that other cells,
such as activated platelets release sCD154. Cell-bound as
well as sCD154 have been shown to activate endothelial
cells in vitro, and increase production of leukemia inhibi-
tory factor, IL6 and granulocyte-macrophage colony stim-
ulating factors [14]. We speculate that sCD154 could
possibly interact with cells bearing CD40, possibly
enhancing antigen presentation, and production of other
inflammatory mediators in JIA.
Table 4: Cytokine levels in sera of healthy controls and in patients with different JIA subtypes.
Cytokine Controls
N = 130
Systemic
N = 10
Poly RF+
N = 10
Poly RF-
N = 14
Persistent 
oligo
N = 20
Extended 
Oligo
N = 11
ERA
N = 11
IL1β 0.6 (0–143) 6.8 (3–407)§ 100.4 (0–1000)§ 13.4 (0–1000)§ 5.6 (0–289)† 29.7 (0–1000)‡ 6.3 (1–656)†
IL6 0.6 (0–19) 34.2 (3–980)§ 36 (1–1000)§ 17 (0.9–1000)§ 7.6 (1–1000)§ 5.6 (1–1000)§ 14.2 (2–99)§
IL8 2 (0–9) 14.2 (0–103)‡ 62.6 (0–1000)§ 63.3 (0–1000)† 12.4 (0–380)§ 20.3 (0–1000) 0 (0–81)
IL10 2.0 (0–32) 6.7 (1–46)* 7.1 (1–40)* 3.9 (1–14)* 1.8 (0–42) 1.8 (0–10) 2.7 (1–76)
IL13 0.8 (0–15) 0 (0–427) 83.3 (0–1152)‡ 48.4 (0–980)† 0 (0–1300)* 19 (0–396)* 19.4 (0–1367)*
sCD154 19 (0–599) 327 (89–609)§ 408 (35–2382)§ 203 (40–596)§ 180 (0–390)* 180 (60–360)§ 379 (57–2996)§
sIL2R 785 (180–1505) 1184 (703–
3000)‡
1057 (174–
2662)*
1355 (176–
3000)*
501 (100–1762) 895 (273–2173) 822 (361–3000)
TNFα 0 (0–233) 22.8 (0–335)§ 47.6 (0–564)§ 24.3 (0–498)§ 0 (0–191)* 66.8 (0–435)§ 15 (0–1000)§
Poly RF+, rheumatoid factor positive polyarticular JIA; Poly RF-, rheumatoid factor negative polyarticular JIA; oligo, oligoarticular JIA; ERA, 
enthesitis related arthritis; IL, Interleukin; sCD154, soluble CD154; sIL2R, soluble IL2 receptor; TNFα, tumor necrosis factor-α;
All values median (range) are expressed in pg/ml. Values of sIL2R and sCD40L levels, as well as ranges of all cytokines have been rounded to the 
nearest number.
* Significant difference between controls and patients; p < 0.05.
‡ Significant difference between controls and patients; p < 0.01
† Significant difference between controls and patients; p < 0.001;
§Significant difference between controls and patients; p < 0.0001.Pediatric Rheumatology 2008, 6:8 http://www.ped-rheum.com/content/6/1/8
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Our correlation analyses showed significant association
between sCD154 and the pro-inflammatory markers IL6,
IL1 β, IL8 and TNFα. It has been shown that sCD154 has
the potential to activate endothelial cells in vitro, and
increase production of IL6 [14]. Elevated levels of IL6 in
JIA have been reported by several authors [2-7,33,34].
Indeed, levels of IL6 were strikingly higher among all JIA
subtypes compared to controls in our study. IL6 was also
significant in the logistic regression analysis suggesting
that it likely plays a major role in concert with other
cytokines in the pathogenesis of JIA. The increased levels
of the pro-inflammatory cytokines IL1β and IL8 observed
in our cohort have also been reported in different forms of
JIA as well as RA [3-5,8,35]. In agreement with earlier find-
ings, we observed that levels of TNFα were elevated in all
subtypes except those with persistent oligoarticular JIA, in
which fewer joint involvement and less systemic inflam-
mation is observed [6,8]. Together these observations sup-
port a primary or secondary role for the inflammatory
cytokines IL6, IL1β, IL8 and TNFα in different JIA sub-
types.
The elevated levels of sIL2R and IL10 in the different sub-
types of JIA are in agreement with previous studies [2,6,9]
although with some subtle differences which may be
attributable to the differences in the size of the cohorts.
For example, although we observed increased levels of
sIL2R in a JIA subtype equivalent to ERA in a study by
Mangge et al [8], these concentrations were not signifi-
cantly different from controls. Nevertheless, sIL2R levels
tend to be highest in systemic or polyarticular JIA suggest-
ing that it maybe a biomarker of JIA. Our logistic regres-
sion analysis suggests that IL10 might have a protective
effect on disease, as might be anticipated by its inhibitory
activity.
Some cytokines were barely detected in the serum in a
majority of subjects detected in our study. For example,
undetectable levels of IL2, and IFNγ have been reported by
other investigators [34,36]. On the other hand, some of
the results described here have not previously been
reported by others. For instance some authors have
reported finding no significant elevations in the levels of
IL1β, IL8, or TNFα [2,4,8,33]. Differences in the results
reported in this study and others could reflect heterogene-
ity of the different JIA cohorts. Other differences could be
due to methodological issues, such as test specimen
(serum versus plasma) and assay methodology. It is likely
that some cytokines are more elevated in the synovial
fluid and not in the serum, especially in children with per-
sistently oligoarticular JIA.
Our study has several strengths. Our cohort of ~80 JIA
patients and 80 pediatric controls is larger than most
series. Our patients have been classified using the ILAR cri-
teria, which results in more homogeneous subtypes com-
pared to earlier studies. To our knowledge sCD154 has
not been measured in JIA patients before. We also meas-
ured several other cytokines previously implicated in JIA.
The multiplex assay used small volumes of serum to assay
thirteen cytokines. This method has also been successfully
used by de Jager et al[33], but sCD154 and sIL2R were not
among the cytokines included in their study. They also
found that IL6 differed between controls and patients. We
have used an objective partially automated multianalyte
assay which we have found to reliably measure cytokines
and other analytes in a variety of disorders including
immune deficiency [26], coronary artery disease [37] and
acute rheumatic fever [38]. We believe the differences in
cytokine profiles, as well as in the inflammatory marker
sCD154, suggest that these might play a role in the patho-
genesis of at least some subtypes of JIA.
The past decade has seen the emergence of biological ther-
apeutic agents directed against several mediators of
inflammation. Our findings of elevated TNFα is in agree-
ment with the response seen with anti-TNF therapy in
children with JIA. The elevated levels of IL1β and IL6 sup-
port the roles for biological agents targeting these
cytokines as well. Finally, sCD154 could also be a poten-
tial target of biological therapy, although some studies in
individuals with SLE raise the concern for pro-thrombotic
effects, possibly due to effects of these agents on platelets
sCD154 Levels among controls and children with different  JIA subtypes Figure 1
sCD154 Levels among controls and children with dif-
ferent JIA subtypes. Levels of sCD154 in different JIA sub-
types. The boundaries of the boxes correspond to the 25th 
and 75th percentile. The solid horizontal line within the box 
denotes the median value and the dashed lines represent the 
mean values. The Whiskers above and below the boxes show 
the 90th and 10th percentiles respectively. Four subjects had 
levels greater than 1000 pg/ml.
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and/or the endothelium [39]. If the importance of the
CD40–CD154 pathway in JIA is confirmed, and safety
concerns could be addressed, therapy directed at inhibit-
ing this pathway deserves further exploration in JIA.
Conclusion
We have demonstrated that sCD154 levels are elevated in
sera from children with JIA. Furthermore, sCD154 levels
correlated with several other pro-inflammatory cytokines,
which are also elevated in children with JIA. The potential
implications of sCD154 as a biomarker for treatment and
monitoring patients is of particular appeal since sCD154
is a molecule associated with T cell activation and may
play a role in the pathogenesis of JIA.
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